2011; Njau et al. 2020). Vascular endothelial growth factor and fibroblast growth factor (FGF) are signalling proteins that stimulate angiogenesis. Both VEGFs and FGFs contain a heparin-binding domain (HBD). Heparin and heparan sulphates positively regulate the activity of VEGF. The blockade of these HBD on VEGF and FGF are therapeutic targets to inhibit angiogenesis in several human diseases such as neoplasia, diabetic retinopathy, rosacea or psoriasis (Angulo et al. 2011). This evidence concerns the gene VEGFA and rosacea.